Carvedilol-d4

• Description :

  Carvedilol-d4 is the deuterium labeled Carvedilol. Carvedilol (BM 14190) is a non-selective β/α-1 blocker[1]. Carvedilol inhibits lipid peroxidation in a dose-dependent manner with an IC50 of 5 μM. Carvedilol is a multiple action antihypertensive agent with potential use in angina and congestive heart failure[2]. Carvedilol is an autophagy inducer that inhibits the NLRP3 inflammasome[3].

• Product Name Alternative :

  BM 14190-d4

• UNSPSC :

  12352005

• Target :

  Adrenergic Receptor; Autophagy

• Type :

  Isotope-Labeled Compounds

• Related Pathways :

  Autophagy; GPCR/G Protein; Neuronal Signaling

• Field of Research :

  Cancer; Inflammation/Immunology; Cardiovascular Disease

• Purity :

  99.80

• Solubility :

  10 mM in DMSO|DMSO : 100mg/mL (ultrasonic)

• Smiles :

  COC(C=CC=C1)=C1OC([2H])([2H])C([2H])([2H])NCC(O)COC2=C3C4=CC=CC=C4NC3=CC=C2

• Molecular Formula :

  C24H22D4N2O4

• Molecular Weight :

  410.50

• References & Citations :

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Eggertsen R, et al. Acute haemodynamic effects of carvedilol (BM 14190), a new combined beta-adrenoceptor blocker and precapillary vasodilating agent, in hypertensive patients. Eur J Clin Pharmacol. 1984;27 (1) :19-22.|[3]Feuerstein GZ, et al. Myocardial protection by the novel vasodilating beta-blocker, carvedilol: potential relevance of anti-oxidant activity. J Hypertens Suppl. 1993 Jun;11 (4) :S41-8.|[4]Wong WT, et al. Repositioning of the β-Blocker Carvedilol as a Novel Autophagy Inducer That Inhibits the NLRP3 Inflammasome. Front Immunol. 2018 Aug 22;9:1920.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Isotope-Labeled Compounds

• Clinical Information :

  No Development Reported

• CAS Number :

  [1133705-56-2]